HCID 68843025, compound → HCID 57777286, compound

HRID 660702Notes

Reaction equation

HRID 660702 reaction equation
[K].C([O:9][C:10]1[CH:15]=[C:14]([CH2:16][CH:17]([CH3:26])[C:18](=[O:25])[C:19]2[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=2)[CH:13]=[CH:12][C:11]=1[N:27]1[S:31](=[O:33])(=[O:32])[NH:30][C:29](=[O:34])[CH2:28]1)C1C=CC=CC=1>CCO.O.[Pd]>[OH:9][C:10]1[CH:15]=[C:14]([CH2:16][CH:17]([CH3:26])[C:18](=[O:25])[C:19]2[CH:20]=[CH:21][CH:22]=[CH:23][CH:24]=2)[CH:13]=[CH:12][C:11]=1[N:27]1[S:31](=[O:33])(=[O:32])[NH:30][C:29](=[O:34])[CH2:28]1

Participants

4

Reactant 1

HCID 68843025HCID 68843025, compound

Product 1

HCID 57777286HCID 57777286, compound

Reagents, catalysts & solvents 2

HCID 23938PalladiumCatalystHCID 19096565Water ethanolSolvent

Procedure

A solution of 5-[2-benzyloxy-4-(2-methyl-3-oxo-3-phenylpropyl)-phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one potassium salt (15 mg) in 4 mL of EtOH/water (1:1) is hydrogenated over Degussa Pd/C (5 mg) at 1 atm for 15 min. The catalyst is filtered and the solvent is removed under reduced pressure. The residue is purified by reverse phase HPLC followed by lyophilization to give the title compound. (M−1)−=373. HPLC retention time=1.13 min (Method A).

Workup

  1. filtrationThe catalyst is filtered
  2. customthe solvent is removed under reduced pressure
  3. customThe residue is purified by reverse phase HPLC

Sources & evidence

ORD record
ord-89640b9ff517479d80486ef963bfd4b9
Source dataset
uspto-grants-2011_12
Patent number
US08084448B2

Reaction notes

Loading…